Paul Hastings, Covington Guide Kyverna's Upsized $319M IPO
Cell therapy firm Kyverna Therapeutics Inc. soared 36% in debut trading Thursday after completing an upsized $319 million initial public offering above its price range, guided by Paul Hastings LLP and...To view the full article, register now.
Already a subscriber? Click here to view full article